Progress in the US With Biosimilars, but Opportunities Remain

Last year was a big year for biosimilars in the United States, with the number of FDA-approved biosimilars nearly doubling and major policy and regulatory developments taking place.

Last year was a big year for biosimilars in the United States, with the number of FDA-approved biosimilars nearly doubling and major policy and regulatory developments taking place in 2018. Kelly Davio, senior editor of AJMC®'s The Center for Biosimilars®, highlights recent progress, how the US market compares with Europe, and what remains to be seen.

You may need to log in to the website to access this podcast.

iTunes